GLP-1 drug pipeline tracker

Several next-generation GLP-1 and multi-receptor drugs are moving through clinical trials. As each one earns FDA approval, it becomes a candidate for Medicare Part D and Bridge coverage — potentially expanding options and, over time, increasing competition on price. Below we track the most-watched candidates. Phases and dates are estimates and change as trials report out.

FDA approval is the first gate. After that, a drug must be added to a Part D plan's formulary and meet the Bridge program's qualifying-condition rules before it's covered for you. New approvals can take months to a year-plus to appear on formularies, and prior authorization usually applies. We'll update this tracker as candidates advance.

Every drug on this page is somewhere on the same path, and knowing where helps you judge how soon it might matter. Phase 1 tests basic safety in a small group. Phase 2 looks at whether the drug works and at the right dose. Phase 3 is the large trial that compares the drug against a placebo or existing treatment — it's the data the FDA leans on most. After a successful Phase 3, the maker files for approval and the FDA reviews. A candidate marked "Phase 3" or "Filed" is far closer to a pharmacy shelf than one in Phase 2, but nothing is guaranteed: trials can miss their targets, and timelines routinely slip.

A crowded pipeline is good news for patients for two reasons. The first is choice: different mechanisms — triple agonists like retatrutide, oral pills like orforglipron, amylin combinations like CagriSema — mean more ways to match a medication to a person's biology and tolerance. The second is price. Today's GLP-1 market is dominated by a few brand-name injectables with little direct competition, which keeps list prices high. As more drugs win approval, and as the first generics eventually arrive later this decade, that competition tends to push prices down.

That said, price relief from competition is a slow process measured in years. If you're eligible now, the Medicare GLP-1 Bridge program's flat $50 monthly copay is the faster route to an affordable prescription — and it applies to the medications already covered today, not the ones still in trials. Use this tracker to see what's coming, but don't wait on it if a covered option already fits your situation.